The Journal of Neuroscience, June 16, 2004, 24(24):5549-5559; doi:10.1523/JNEUROSCI.2719-03.2004
Previous Article | Next Article 
Cellular/Molecular
Morphine-Induced Changes in 
Opioid Receptor Trafficking Are Linked to Somatosensory Processing in the Rat Spinal Cord
Anne Morinville,1,2
Catherine M. Cahill,1
Haneen Aibak,1
Vladimir V. Rymar,1
Amynah Pradhan,2
Cyrla Hoffert,3
Françoise Mennicken,3
Thomas Stroh,2
Abbas F. Sadikot,1
Dajan O'Donnell,3
Paul B. S. Clarke,2
Brian Collier,2
James L. Henry,4
Jean-Pierre Vincent,5 and
Alain Beaudet1
1Montreal Neurological Institute, McGill University, Montreal, Québec, Canada H3A 2B4, 2Department of Pharmacology and Therapeutics, McGill University, Montreal, Québec, Canada H3G 1Y6, 3Department of Molecular Sciences, AstraZeneca R&D Montreal, Montreal, Québec, Canada H4S 1Z9, 4Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada N6A 5C1, and 5Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université de Nice, 06560 Valbonne, France
 |
Abstract
|
|---|
An in vivo fluorescent deltorphin (Fluo-DLT) internalization assay was used to assess the distribution and regulation of pharmacologically available 
opioid receptors (ORs) in the rat lumbar (L4-5) spinal cord. Under basal conditions, intrathecal injection of Fluo-DLT resulted in the labeling of numerous OR-internalizing neurons throughout dorsal and ventral horns. The distribution and number of Fluo-DLT-labeled perikaryal profiles were consistent with that of OR-expressing neurons, as revealed by in situ hybridization and immunohistochemistry, suggesting that a large proportion of these cells was responsive to intrathecally administered OR agonists. Pretreatment of rats with morphine for 48 hr resulted in a selective increase in Fluo-DLT-labeled perikaryal profiles within the dorsal horn. These changes were not accompanied by corresponding augmentations in either OR mRNA or 125I-deltorphin-II binding levels, suggesting that they were attributable to higher densities of cell surface OR available for internalization rather than to enhanced production of the receptor. Unilateral dorsal rhizotomy also resulted in increased Fluo-DLT internalization in the ipsilateral dorsal horn when compared with the side contralateral to the deafferentation or to non-deafferented controls, suggesting that OR trafficking in dorsal horn neurons may be regulated by afferent inputs. Furthermore, morphine treatment no longer increased Fluo-DLT internalization on either side of the spinal cord after unilateral dorsal rhizotomy, indicating that µOR-induced changes in the cell surface availability of OR depend on the integrity of primary afferent inputs. Together, these results suggest that regulation of OR responsiveness through µOR activation in this region is linked to somatosensory information processing.
Key words: opiate; morphine; internalization; fluorescence microscopy; targeting; narcotic; intrathecal; dorsal rhizotomy
|
Introduction
|
|---|
Endogenous as well as exogenous opioids exert their effects through interaction with three major opioid receptor (OR) subtypes, referred to as µ, , and 
, belonging to the G-protein-coupled receptor (GPCR) superfamily (Evans et al., 1992
; Kieffer et al., 1992; Chen et al., 1993; Fukuda et al., 1993; Meng et al., 1993; Thompson et al., 1993; Wang et al., 1993; Yasuda et al., 1993). All ORs are implicated in the modulation of pain transmission, but µOR-acting agonists are currently preferred for the management of moderate to severe pain. However, the clinical use of µ opioid drugs is limited by their tendency to cause tolerance and dependence with prolonged or repeated administration and to elicit undesirable effects such as respiratory depression, nausea, and constipation (for review, see Colpaert, 1996; Kreek, 1996). In contrast, OR-acting drugs reportedly produce fewer undesirable effects than µOR-acting ones and thereby offer an attractive alternative for pain relief.
Solid anatomical evidence supports a role for OR in the regulation of spinal nociceptive pathways. Indeed, ligand binding (Fields et al., 1980; Zajac et al., 1989; Besse et al., 1990, 1992a,b,c; Stevens and Seybold, 1995; Mennicken et al., 2003), in situ hybridization (Mansour et al., 1994a; Ji et al., 1995; Minami et al., 1995; Wang and Wessendorf, 2001; Mennicken et al., 2003), and immunohistochemical (Dado et al., 1993; Zhang et al., 1998; Abbadie et al., 2002) data concur in demonstrating the presence of OR in dorsal root ganglia and primary afferent terminals in the dorsal horn of mammalian spinal cord. Furthermore, an important population of intrinsic dorsal and ventral horn neurons has been documented to express (Mansour et al., 1994a; Maekawa et al., 1996; Wang and Wessendorf, 2001; Cahill et al., 2001a, 2003; Mennicken et al., 2003) and synthesize (Dado et al., 1993; Arvidsson et al., 1995; Zhang et al., 1998; Mailly et al., 1999; Robertson et al., 1999; Cahill et al., 2001a) OR in both nonhuman primate and rodent spinal cord. Surprisingly, only a small proportion of ORs is present on the surface of neurons under basal conditions (Cheng et al., 1995, 1997; Elde et al., 1995; Zhang et al., 1998; Cahill et al., 2001a). However, a number of experimental paradigms, including chronic pain, cell depolarization, or specific drug treatments (Cahill et al., 2001b, 2003; Petaja-Repo et al., 2002; Bao et al., 2003; Morinville et al., 2003), can increase targeting of OR to the plasma membrane.
We recently showed that prolonged pretreatment of rats with µOR agonists promotes the recruitment of OR to neuronal plasma membranes in the dorsal horn of the lumbar spinal cord, an effect associated with increased effectiveness of intrathecally injected OR agonists (Cahill et al., 2001b; Morinville et al., 2003). However, the mechanisms that underlie this increased OR targeting have not been elucidated fully at the systems level. Therefore, a first aim of this study was to determine whether all neurons that express ORs in the gray matter of the lumbar spinal cord are affected by µOR agonist pretreatment.
A number of studies has demonstrated that an important proportion of spinal µORs are associated with primary afferent terminals arborizing in laminas I-II (Fields et al., 1980; Zajac et al., 1989; Besse et al., 1990, 1992a,b,c; Gouardères et al., 1991; Stevens and Seybold, 1995; Ding et al., 1996; Abbadie et al., 2002). Thus, a second aim of this study was to determine whether the upregulation of cell surface ORs produced by prolonged treatment with µOR agonists could still be elicited in rats lacking afferent primary inputs.
To address these questions, an assessment of the cell surface availability of ORs had to be made over the entire gray matter of the lumbar spinal cord. Traditional receptor visualization techniques are restrictive in their sampling extent (e.g., electron microscopic immunocytochemistry), their ability to discriminate between pharmacologically available and intracellular reserve receptors (e.g., receptor autoradiography or immunohistochemistry), or their cellular resolution (e.g., binding of a nonhydrolysable analog of GTP). Therefore, we developed an assay on the basis of the property of surface-bound peptide agonists to undergo receptor-mediated endocytosis (Ferguson, 2001; Pierce and Lefkowitz, 2001), whereby the cell surface availability of ORs was indirectly assessed through measurement of the internalization of an in vivo-administered fluorescent OR agonist.
|
Materials and Methods
|
|---|
Animals. Experiments were performed in adult male Sprague Dawley rats (200-250 gm; Charles River, Québec, Canada) housed in groups of two per cage. Rats were maintained on a 12 hr light/dark cycle and were allowed free access to food and water. Studies were conducted during the light phase of the cycle. Experiments were approved by the animal care committee at McGill University and complied with the policies and directives of the Canadian Council on Animal Care. Control or nonmorphine-pretreated animals refer to either untreated or saline-pretreated rats (0.9% NaCl subcutaneously; every 12 hr, four injections; experiments were performed 12 hr after the last injection). Morphine pretreatment for 48 hr refers to animals that were treated with increasing doses of morphine sulfate (MS; 5, 8, 10, and 15 mg/kg subcutaneously) every 12 hr; experiments took place 12 hr after the last injection.
In vivo OR internalization assay. Internalized fluorescent OR agonist, 
-Bodipy 576/589 deltorphin-I 5-aminopentylamide (Fluo-DLT) prepared as described previously (Gaudriault et al., 1997), was visualized in the rat lumbar (L4-5) spinal cord using confocal microscopy. For this purpose, rats were anesthetized with sodium pentobarbital (intraperitoneal administration, 7.7 mg/100 gm) and injected intrathecally via a lumbar puncture with 0.8 nmol Fluo-DLT diluted in 30 µl of saline at the L5-6 intervertebral space. For specificity controls, rats were injected both subcutaneously and intrathecally with 1.6 µmol of nonfluorescent naloxone 15 min before intrathecal administration of Fluo-DLT. Rats were killed 20 min after injection of the fluorescent ligand by intra-aortic arch perfusion of, in succession, 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; 500 ml, pH 7.4) at 4°C, 10% sucrose in 0.2 M PB (100 ml, pH 7.4), 20% sucrose in 0.2 M PB (100 ml, pH 7.4), and 30% sucrose in 0.2 M PB (100 ml, pH 7.4). Lumbar segments of the spinal cord were snap-frozen in isopentane at -45°C and stored on dry ice or at -80°C until sectioning. Frozen tissue was transversely sectioned at the L4-5 lumbar segment at a thickness of 20 µm on a cryostat and thaw-mounted onto chrome alum/gelatin-coated slides.
Sections were visualized (without coverslips) using a Zeiss confocal laser scanning microscope LSM510 (Zeiss, Toronto, Ontario, Canada) equipped with an inverted microscope (oil-immersion objectives, 40x and 63x), an Argon laser with an excitation wavelength of 488 nm and a helium/neon laser with an excitation wavelength of 543 nm. Representative images were acquired within each lamina for three to five sections per animal on either or both sides of the cord when the two sides were identical or on both sides when they differed. Acquired images were processed using Zeiss LSM Image browser version 3 and Photoshop version 6.0 (Adobe Systems, San Jose, CA) on an IBM compatible computer.
Perikaryal profiles displaying internalized Fluo-DLT (i.e., intracytoplasmic fluorescent puncta) within each lamina were counted in three to five animals per experimental condition, ensuring that section thickness, number of sections sampled (n = 10 per animal), and acquisition parameters were constant between paired experimental groups. Only profiles in which the nucleus could be clearly discerned were counted. In cases where both sides of the cord were identical, cell profiles were counted on both sides and averaged for each section within each lamina. To ensure that differences in the number of labeled perikaryal profiles between experimental groups reflected changes in the number of cells having internalized Fluo-DLT and not in the size or packing of labeled neurons, the cross-sectional area of Fluo-DLT-labeled profiles was measured in laminas III-V of the dorsal horn using the NIH ScionImage software program (Scion, Frederick, MD) and averaged for each lamina in each animal for both control and morphine-pretreated rats.
Global fluorescence intensity levels over entire confocal microscopic images were quantified by converting the images to a gray scale. Subsequently, using the thresholding function of ScionImage, the Fluo-DLT fluorescence-labeling area above the set threshold was estimated within a standard area; fluorescence-labeling levels within this area were expressed in arbitrary units (AU).
Calculations and statistical analyses were performed using Excel 97 (Microsoft, Seattle, WA), SYSTAT 10.2 (Systat, Richmond, CA), and Prism 3.02 (Graph Pad, San Diego, CA). See figures for specific statistical analysis details.
Neuronal staining. Neuronal phenotype in Fluo-DLT-labeled sections was verified using the Neurotracer Fluorescent Nissl stain according to the instructions of the manufacturer (Molecular Probes, Eugene, OR). Briefly, fluorescently labeled sections were incubated for 30 min with 0.1 M PBS, pH 7.4, washed twice with 0.1 M PBS, and incubated for 20 min with Neurotracer diluted 1:50 in 0.1 M PBS. Sections were then rinsed twice with 0.1 M PBS, washed with 0.1 M PBS for 1 hr, mounted with Aquamount, and visualized by confocal microscopy.
Light microscopic immunolabeling of rat brain sections. To compare the number of perikaryal profiles displaying internalized Fluo-DLT with that exhibiting OR-immunoreactive proteins, immunopositive perikaryal profiles were counted in sections from the rat spinal cord processed for immunohistochemical detection of OR in a previous study (Cahill et al., 2001a). In this study, rats were anesthetized with sodium pentobarbitol (70 mg/kg, intraperitoneal) and perfused through the aortic arch with a freshly prepared solution of 4% PFA in 0.1 M PB (500 ml, pH 7.4) at 4°C. Spinal cords were then postfixed in the same fixative solution by immersion for 30 min followed by overnight cryoprotection in 30% sucrose in 0.2 M PB, both at 4°C. After 24 hr, tissue was snap-frozen in isopentane at -45°C. Immunohistochemistry was performed according to the avidin biotinylated-horseradish-peroxidase complex (ABC) method using a standard ABC kit (Vector Laboratories, Burlingame, CA) and a biotinyltyramide amplification system. Transverse (30 µm) sections were cut on a freezing microtome. Free-floating sections were washed with 0.1 M TBS, pH 7.4, followed by preincubation for 1 hr in a blocking solution containing 3% NGS and 6% bovine serum albumin (BSA) at room temperature. Serial sections were then incubated at 4°C for 48 hr with Quality Controlled Biochemicals (lot number 4430402) or Chemicon (Temecula, CA; lot numbers 17080164, 20010505, 20100177) OR antisera diluted to 0.2-0.5 µg/ml in TBS containing 1% BSA (TBS-BSA). After rinsing in TBS-BSA (three times for 10 min each), the sections were incubated at room temperature for 45 min in biotinylated goat anti-rabbit IgG (BIO-CAN Scientific, Mississauga, Ontario, Canada) diluted 1:100 in TBS-BSA followed by a 50 min incubation in ABC solution prepared according to the instructions of the manufacturer. Sections were then incubated in a solution of 0.1% biotinylated tyramide, activated with 0.01% H2O2 in TBS-BSA for 10 min, and subsequently subjected to a second 50 min incubation with ABC. Visualization of the biotin-bound peroxidase was achieved in some instances by the use of 0.05% DAB, 0.01% H2O2, and 0.04% nickel chloride in 0.1 M Tris buffer, pH 7.4, to produce a black precipitate. Sections were mounted on chrome alum/gelatin-coated slides, air dried, dehydrated with ethanol of increasing concentrations, cleared in xylene, mounted with Permount (Fisher Scientific, Houston, TX), and examined with a Leitz Aristoplan photomicroscope (Leica, Richmond Hill, Ontario, Canada). Perikaryal profiles displaying immunoreactive OR within each lamina (L4-5) were counted in sections from three animals. Only profiles in which the nucleus could be clearly discerned were counted. Data were expressed as means ± SEM.
Determination of OR mRNA expression. To investigate the effects of chronic morphine treatment on the expression of OR mRNA, control (n = 4) and morphine-pretreated (n = 4) rats were killed by decapitation 12 hr after the last morphine injection. Spinal cords were quickly removed and snap-frozen in isopentane at -40°C for 30 sec and stored at -80°C. Frozen tissue was transversely sectioned at 14 µm on a cryostat and thaw-mounted onto ProbeOn Plus slides (Fisher Scientific). Slides were stored at -80°C until additional use.
The OR sense and antisense probes were transcribed in vitro using Uridine 5'-[
-35S]thiotriphosphate and cytidine 5'-[-35S]thiotriphosphate (
800 Ci/mmol; Amersham Biosciences, Oakville, Ontario, Canada) and T7 or SP6 RNA polymerase (Amersham Biosciences), respectively, from the full-length human OR sequence (1.2 Kb) cloned into pcDNA3 and linearized using XbaI or HindIII restriction enzymes (Promega, Madison, WI; New England Biolabs, Mississauga, Ontario, Canada). After transcription, the DNA template was digested with DNase I (Amersham Biosciences). Riboprobes were subsequently purified using G-50 Sepharose microspin columns (Amersham Biosciences). The probes were then hydrolyzed at 60°C for 15 min in 1 M carbonate buffer [0.4 M NaHCO3, 0.6 M Na2CO3 in diethyl pyrocarbonate (DEPC)-treated H2O, pH 9.8] followed by a combined neutralization and precipitation step on dry ice for 30 min with ethanol containing 25 M sodium acetate, 0.15% acetic acid, 15 µg/ml yeast tRNA, and 0.15 M ammonium acetate. After centrifugation, the pellets were air-dried and resuspended in DEPC-treated H2O containing 20 mM dithiothreitol (Sigma, St. Louis, MO). The quality of labeled riboprobes and their hydrolysis was verified qualitatively by polyacrylamide-urea gel electrophoresis and scintillation counting.
In situ hybridization for OR was performed as described previously (Cahill et al., 2001a, 2003; Mennicken et al., 2003) on the sections processed as described above using hydrolyzed probes. Although the same pattern of distribution in the CNS has been obtained with hydrolyzed and nonhydrolyzed mRNA OR probes on adjacent sections, a stronger signal was obtained with the hydrolyzed probe, suggesting a better penetration of this probe compared with the nonhydrolyzed probe. Briefly, sections were fixed with 4% PFA, rinsed three times in 2x standard sodium citrate buffer (SSC), equilibrated in 0.1 M triethanolamine, and treated with 0.25% acetic anhydride in 0.1 M triethanolamine. After a rinse in 2x SSC and dehydration through an ethanol series (50-100%), hybridization was performed in a buffer containing 75% formamide (Sigma), 600 mM NaCl, 10 mM Tris HCl, pH 7.5, 1 mM EDTA, 1x Denhardt's solution (Sigma), 50 µg/ml denatured salmon sperm DNA (Sigma), 10% dextran sulfate (Sigma), 20 mM dithiothreitol, and [35S]-labeled cRNA probe (20 x 106 cpm/ml) at 55°C for 18 hr in chambers humidified with 75% formamide. After hybridization, slides were rinsed in 2x SSC at room temperature, treated with 20 µg/ml RNase IA in RNase buffer (25 mM NaCl, 5 mM Tris HCl, pH 7.5, 0.5 mM EDTA) for 45 min at 37°C, and washed to a final stringency of 0.1x SSC at 70°C. Sections were then dehydrated, and slides were dipped in Kodak (Rochester, NY) NTB2 emulsion diluted to 1:1 with distilled water and exposed for 8-10 weeks at 4°C before being developed with Kodak D-19 developer. Slides were then counterstained with toluidine blue and viewed on a Leitz Aristoplan photomicroscope (Leica).
Densitometric quantification of mRNA expression was determined on lumbar segment 4-5 of morphine-pretreated and control animals using a Biocom computer-assisted image analysis system (Historag, Les Ulis, France). Silver grains were counted in four to eight selected regions throughout laminas I-II, III-V, VIII, and IX for at least three spinal cord sections per animal. The total number of grains in each of the selected regions was averaged to give a total grain count per laminar region (i.e., I-II or III-V) for each section of a given animal; laminar counts for each section were averaged in turn to yield values for each animal. The grain counting and region selection was performed by an experimenter who was not aware of the treatment. Statistical details are provided in the figures. In addition, the number of cell bodies labeled by in situ hybridization was counted in six 14 µm sections selected at random from four control rats. Data are presented as means ± SEM.
Autoradiographic detection of [125I]-deltorphin-II binding sites. Serial sections adjacent to those used for in situ hybridization were processed for receptor autoradiography using [125I]-deltorphin-II ([125I]-DLT-II) (Plobeck et al., 2000). The peptide (BACHEM Bioscience, King of Prussia, PA) was iodinated according to the chloramine T method as described previously (Fraser et al., 1999) (specific activity, 2200 Ci/mmol). Sections were preincubated for 30 min at room temperature in 50 mM Tris-HCl, 120 mM NaCl, and 1 mM MgCl2 buffer, pH 7.4, and then incubated for 60 min at room temperature in the same buffer containing 0.5% BSA, 0.1 mM Bestatin, 0.1 mM PMSF, and 50 pM [125I]-DLT-II. Nonspecific binding was determined in the presence of 1 µM naltrindole. Sections were washed three times for 3 min each in ice-cold Tris-HCl buffer, air dried, and exposed to Kodak BioMax MS film for 2 weeks.
Signal intensity was measured over individual lamina of both dorsal and ventral horn of the L4-5 segment using the MCID imaging analysis system (Imaging Research, St. Catherines, Ontario, Canada) for both control and morphine-pretreated animals (n = 4 rats/group; three to four sections per animal). Film autoradiograms were digitized using the MCID image analysis system equipped with a high resolution Xillix Microimager digital camera (Xillix Technologies, Richmond, BC). Images were processed using Photoshop version 6.0 imaging software (Adobe Systems) on an IBM-compatible computer. Details of the statistical analysis are provided in the figures.
Autoradiographic detection of GTP
S binding. To assess the effect of chronic morphine treatment on OR activation, control (n = 14) and morphine-pretreated (n = 13) rats were killed by decapitation 12 hr after the last morphine injection as above. Spinal cords were quickly removed and snap-frozen in isopentane at -40°C for 30 sec and stored at -80°C. Frozen tissue was transversely sectioned at 14 µm on a cryostat and thaw-mounted onto ProbeOn Plus slides or chrome alum/gelatin-coated slides. Slides were stored at -80°C until additional use. Agonist-stimulated GTPS (a nonhydrolysable analog of GTP) binding was assessed using a procedure adapted from Hyytia et al. (1999). Briefly, sections were thawed to room temperature and rehydrated for 20 min in assay buffer containing 50 mM Tris HCl, 5 mM MgCl2, 100 mM NaCl, and 1 mM EDTA, pH 7.4. Slides were then pre-incubated for 1 hr with assay buffer plus 2 mM GDP (Sigma) and 1 µM 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; Sigma). The slides were then incubated for 1.5 hr with assay buffer plus 2 mM GDP, 1 µM DPCPX, 1 mM DTT, 225 pM guanosine 5' (-35S-thio) triphosphate ([35S]GTPS; 1250 Ci/mmol; PerkinElmer Life Sciences, Woodbridge, Ontario, Canada), and 0.03-10 µM of the selective OR agonist [D-Ala2]-deltorphin II (DLT; Sigma). Binding of [35S]GTPS in the absence of DLT (basal binding) was determined for each rat. Binding of [35S]GTPS in the absence of DLT and in the presence of 10 µM unlabeled GTPS was also determined for each rat (nonspecific binding). Sections were rinsed in ice-cold buffer containing 50 mM Tris HCl and 5 mM MgCl2 (pH 7.4, twice for 5 min) followed by distilled deionized water (2 sec). They were then blow-dried thoroughly and exposed to Kodak BioMax MR film overnight.
Signal intensity of the autoradiograms was measured in the left and right gray matter of the lumbar L4-5 segment of the rat spinal cord using the MCID imaging analysis system for both control and morphine-pretreated animals (n = 13-14 rats/group; three to six sections per animal). Two series of 14C standards (American Radiolabeled Chemicals, St. Louis, MO) were used to determine GTPS binding levels in femtomoles per milligram. An average in each condition (basal, nonspecific, and DLT 0.03-10 µM) in femtomoles per milligram was thereby obtained for each individual animal. The average nonspecific binding level for each animal was subtracted from determinations for that animal. All DLT-induced GTPS binding values were then divided by the average basal for each animal (expressed as a percentage). Film autoradiograms were digitized using the MCID image analysis system equipped with a high-resolution digital camera. Images were processed using Photoshop version 6.0 imaging software on an IBM-compatible computer. Statistical calculations were made as described in the figures.
Dorsal rhizotomy. To assess the influence of primary afferent pathways on morphine-induced OR cell surface recruitment, rats were subjected to a unilateral dorsal rhizotomy before chronic morphine treatment. Rats (n = 6) were anesthetized by administration of a mixture of ketamine (60 mg/kg) and xylazine (6 mg/kg), placed in a holding apparatus, and subjected to a T11 to L3 laminectomy under aseptic conditions. Anesthetic supplements were injected throughout the surgical procedure as needed. Under a dissecting microscope, the dura mater was cut, and dorsal roots corresponding to spinal segments L1 to L5 (or L6) were identified and transected (lidocaine was applied locally to facilitate this process). Care was taken not to damage blood vessels or spinal tissue. After root transection, the exposed spinal cord was covered with saline-moistened Gel-foam, and the area was sutured in two layers (muscle and skin). The antibiotic Tribrissen (0.013 ml per 100 gm) was administered once per day, starting 1 d before the surgery and for 3 d after surgery; a topical antibiotic (Cicatrin; Glaxo Wellcome, Montreal, Quebec, Canada) was applied over the sutures for 2 d after the surgery. Postsurgical analgesia was provided by application of topical lidocaine/prilocaine for 1 das well as aspirin in Jello for 3-4 d after surgery. After the surgery, individual rats were housed in the presence of a female rat because this practice has been shown to prevent autotomy (Berman and Rodin, 1982).
Surgeries were done in groups of two rats to pair control and morphine-pretreated animals. Saline or morphine injections were initiated 8 d subsequent to the surgery, at least 48 hr before the in vivo OR internalization assay. This assay was performed as described above on the tenth day after surgery. The experimenter counting the number of Fluo-DLT-labeled cells in the spinal cord was not aware of the side of the lesion and the pharmacological treatment.
Primary afferent visualization. To confirm degeneration of primary afferent fibers, reactivity for isolectin B4 (IB4) was monitored in sections adjacent to those that were quantified for Fluo-DLT labeling. Sections were washed extensively with 0.1 M PBS before incubation for 1 hr with isolectin GS-IB4 coupled to Alexa 488 (Molecular Probes) diluted 1:500 in 0.1 M PBS. After several washes with 0.1 M PBS, sections were mounted with Aquamount and visualized by confocal microscopy.
|
Results
|
|---|
In vivo internalization of Fluo-DLT
Intrathecal injection of the highly selective fluorescent OR agonist, -Bodipy red-[D-Ala2]-deltorphin I resulted in a punctate fluorescent labeling of numerous nerve cell bodies in all layers of the lumbar spinal cord except in laminas I and II (Figs. 1A,C,E,G,2A,B). Colocalization of a fluorescent Nissl stain with Fluo-DLT confirmed that these fluorescently labeled cells indeed corresponded to neurons (results not shown). Interestingly, labeled neurons were not confined to the outer portion of the spinal cord but were detected throughout the depth of the gray matter, including lamina X (see Fig. 3C for schematic representation).
View larger version (27K):
[in this window]
[in a new window]
|
Figure 1. Antagonism of Fluo-DLT labeling by naloxone in the dorsal and ventral horn of the rat spinal cord. A-H, Anon-pretreated rat (control; A, C, E, G) and a rat pretreated with naloxone (B, D, F, H) were injected intrathecally with 0.8 nmol of Fluo-DLT. Internalized Fluo-DLT is observed by confocal microscopy in dorsal and ventral horn neurons of the lumbar (L4-5) spinal cord; typical images from laminas I-II (A, B), III-IV (C,D), VIII (E, F), and IX (G,H) are presented. Identical acquisition parameters were used to obtain the images for cells labeled in the presence or absence of naloxone. Images are displayed in glow-scale, where white represents the highest fluorescence intensity and red represents the lowest (black indicates the absence of fluorescent signal). Scale bar, 20 µm. I, Fluorescence labeling levels for Fluo-DLT intrathecally injected untreated (control) and naloxone-treated rats were determined as described in Materials and Methods. Each bar corresponds to the average fluorescence labeling levels of the naloxone-treated rat divided by the Fluo-DLT-labeling levels of the untreated rat calculated within each specified lamina (3 sections/animal) in one representative experiment.
|
|
View larger version (29K):
[in this window]
[in a new window]
|
Figure 2. High-magnification confocal microscopic images of Fluo-DLT-labeled neurons in dorsal and ventral horns of the rat spinal cord. Fluorescent puncta (denoted by arrows), corresponding to internalized Fluo-DLT, are evident throughout the perikaryal cytoplasm, sparing the nucleus (N). Images are displayed in glow-scale, where white represents the highest fluorescence intensity and red represents the lowest (black indicates the absence of fluorescent signal). Scale bar, 10 µm.
|
|
View larger version (52K):
[in this window]
[in a new window]
|
Figure 3. Comparison of the localization of cells labeled for OR in the rat lumbar (L4-5) spinal cord. A, B, Immunohistochemical labeling of OR (Fig. 5A) [Cahill et al. (2001a), reprinted with permission] (A) and OR mRNA expression (B), as revealed by in situ hybridization, concur in demonstrating the presence of this receptor in neurons distributed throughout the gray matter of the spinal cord. C, Schematic representation of the distribution of Fluo-DLT-labeled perikaryal profiles in the lumbar spinal cord (L5) (Paxinos and Watson, 1986) of control, non-pretreated rats. The number of filled circles within each lamina represents the average number of Fluo-DLT-labeled cell body profiles per section. D, Comparison of the estimated number of cross-sectioned neurons counted by the three techniques in the dorsal (laminas III-VI) and ventral (VII-IX) horns. Fluo-DLT, immunuhistochemical (IHC)- and in situ hybridization (ISH)-labeled profiles were counted as described in Materials and Methods. Because these three techniques used sections of different thickness, counts were corrected to 20 µm according to the following formula: [(counts x 20)/(section thickness in micrometers)].
|
|
In some cases, Fluo-DLT labeling was seen to extend into proximal dendrites (Fig. 1E). In addition, small individual puncta, presumably contained within cross-sectioned axonal or dendritic processes, were detected throughout the neuropil of the gray matter. This neuropil labeling was particularly dense over laminas I and II (Fig. 1A).
Pretreatment of rats with naloxone before the intrathecal injection of Fluo-DLT almost completely eliminated Fluo-DLT labeling, indicating that the labeling was specific and receptor mediated (Fig. 1B,D,F,H). Densitometric measurements confirmed that >75% of the fluorescent signal was abolished in individual laminas of the spinal cord in naloxone-treated animals (Fig. 1I).
The distribution of Fluo-DLT-labeled perikaryal profiles, as schematized from confocal microscopic observations (Fig. 3C), resembled that of both OR-immunoreactive (Fig. 3A) and OR mRNA-expressing (Fig. 3B) neurons detected in the rat lumbar (L4-5) spinal cord by immunohistochemistry or in situ hybridization, respectively. Comparison of immunohistochemical in situ hybridization and Fluo-DLT labeling data suggest that most OR-expressing neurons in the rat lumbar (L4-5) spinal cord bind and internalize Fluo-DLT in vivo (Fig. 3D).
Effect of morphine pretreatment on Fluo-DLT internalization
We demonstrated previously by electron microscopic immunocytochemistry that morphine pretreatment for 48 hr leads to an increase in the density of OR on the surface of dendrites in the dorsal horn of rodent spinal cord (Cahill et al., 2001b; Morinville et al., 2003). To assess the extent of this upregulation, we used in vivo Fluo-DLT internalization as an indirect assay of cell surface receptor availability.
To quantify the amount of internalized ligand molecules before and after morphine pretreatment, we used two different and complimentary techniques. On one hand, we measured fluorescence intensity levels over individual laminas to provide a global estimate of the labeling over all neuronal elements (cell bodies along with axons and dendrites). On the other hand, we counted the number of Fluo-DLT-labeled perikaryal profiles in each lamina of L4-5 segment. Because nonbiased stereological counting methods were not used, these counts could not be considered absolute. However, they could serve as a basis for comparison between the two treatment groups, provided that morphine treatment did not affect cell size. As seen in Figure 4, administration of morphine under the experimental paradigm used in these studies did not modify the mean cross-sectional area of cells labeled in lamina III-V. This observation suggests that the sizes of Fluo-DLT-labeled cells had likely not been altered by morphine administration.
View larger version (17K):
[in this window]
[in a new window]
|
Figure 4. Cross-sectional area of Fluo-DLT-labeled perikaryal profiles in lamina III-V of the rat spinal cord before and after morphine pretreatment. Control and morphine-pretreated rats were injected intrathecally with 0.8 nmol of Fluo-DLT and subsequently processed for confocal microscopic imaging as described in Materials and Methods. Each bar represents the average cross-sectional area of labeled perikaryal profiles in AU for each animal (n = 3 animals per condition; 5 sections per animal). No statistically significant difference was noted between morphine-pretreated and control rats in either laminas III-IV or V. Statistical significance was determined by means of a repeated measures two-way ANOVA (drug and lamina as variables).
|
|
The distribution pattern of Fluo-DLT-labeled neurons in the lumbar spinal cord was the same in morphine-pretreated as in control rats (Fig. 5A,B). However, the average number of labeled perikaryal profiles per section was significantly greater in laminas III-IV (Fig. 5C) (p < 0.05) and V (Fig. 5C) (p < 0.001) in morphine-pretreated rats than in control animals. The average number of Fluo-DLT-labeled profiles counted after morphine pretreatment was comparable with the number of neuronal profiles labeled by immunohistochemistry in the dorsal horn (compare Figs. 3D and 5C), suggesting that the increased number of labeled profiles detected after morphine pretreatment was attributable to a greater sensitivity in receptor detection within OR-expressing cells than to a greater number of neurons expressing OR. No significant change in the number of Fluo-DLT-positive perikaryal profiles was observed in the ventral horn between morphine-pretreated and control rats (Fig. 5C).
View larger version (38K):
[in this window]
[in a new window]
|
Figure 5. Morphine pretreatment produces a selective increase in the internalization of Fluo-DLT in the dorsal horn of the rat spinal cord. Control and morphine-pretreated rats were injected intrathecally with 0.8 nmol of Fluo-DLT and subsequently processed for visualization by confocal microscopy as described in Materials and Methods. Images of Fluo-DLT internalization from laminas III-IV (A) and V (B) are presented. Images are presented in red-white glow-scale. Scale bar, 10 µm. C, Comparison of the number of Fluo-DLT-labeled perikaryal profiles per section between control and morphine-pretreated rats in the L4-5 spinal cord segment. Each bar represents the average of three independent experiments. Morphine pretreatment produces a significant increase in the number of Fluo-DLT-labeled perikaryal profiles persection in laminas III-IV (denoted by one asterisk; p < 0.05) and in lamina V (denoted by two asterisks; p < 0.001) when compared with control rats. Statistical significance was determined using a two-way ANOVA with drug and lamina as variables. A Bonferroni's multiple comparison test (MCT) was used to determine which lamina, between control and morphine-pretreated animals, displayed a significant difference. D, Morphine pretreatment increased fluorescence-labeling levels when compared with control rats in dorsal horn neurons but not ventral horn neurons. Each bar represents the average of three independent experiments. For D, one asterisk corresponds to p < 0.01, whereas two asterisks representp < 0.001. Statistical significance was determined by means of a repeated measures two-way ANOVA (drug and lamina as variables) with a Bonferroni's MCT to determine which lamina between control and morphine-pretreated animals displayed a significant difference.
|
|
Pretreatment with morphine also resulted in greater overall fluorescence levels throughout the dorsal horn (including laminas I-II) compared with control rats (Fig. 5D). No significant change in overall Fluo-DLT labeling was recorded in the ventral horn between morphine-pretreated and control rats (Fig. 5D).
Effect of morphine pretreatment on OR binding, in situ hybridization, and [35S]-GTPS binding
We then sought to determine whether the morphine-induced increase in Fluo-DLT internalization was accompanied by other detectable changes in OR expression or function. Pretreatment of rats with morphine did not result in any statistically significant change in the density of specific [125I]-DLT-II binding throughout the gray matter of the lumbar (L4-5) spinal cord when compared with control animals (Fig. 6A-C). Similarly, OR mRNA expression, as evidenced by in situ hybridization, remained unchanged in all layers of the lumbar spinal cord after pretreatment with morphine when compared with control animals (Fig. 6D-F).
View larger version (57K):
[in this window]
[in a new window]
|
Figure 6. Morphine pretreatment produces no change in OR agonist binding or mRNA expression. A, B, Binding of 125I-DLT-II in the lumbar (L4-5) spinal cord of control (A) and morphine-pretreated (B) rats. Scale bar, 0.5 mm. C, Densitometric quantification of autoradiographic signal in selected lamina. No significant difference, as assessed by means of a two-way ANOVA followed by a Bonferroni's MCT, was detected between control and morphine-pretreated rats in laminas I-II, III-V, VIII, or IX. Radioligand-binding values (nCi/gm) are based on a 14C series of calibration standards. Each bar represents the mean ± SEM for n = 4 rats per group. D, E, Comparison of OR mRNA expression in the lumbar spinal cord of control (D) and morphine-pretreated (E) rats. Scale bar, 0.25 mm. F, Densitometric quantification of silver grains in selected lamina of the lumbar (L4-5) spinal cord. No significant difference was detected between control and morphine-pretreated rats in laminas I-II, III-V, VIII, or IX (two-way ANOVA followed by a Bonferroni's MCT). Silver grain counts are presented as means ± SEM for n = 4 rats per group.
|
|
In both control and morphine-pretreated rats, incubation of spinal cord sections with DLT resulted in a dose-dependent increase in [35S]-GTPS binding as detected by autoradiography (Fig. 7A,B). The percentage increase over basal GTPS levels was significantly different between the lowest and the highest dose of agonist (Fig. 7C) (unpaired t test; p < 0.05). However, no significant difference between morphine-pretreated and control rats was detected in the spinal gray matter (Fig. 7C).
Contribution of primary afferent inputs to cell surface availability of OR
To determine whether the morphine-induced changes in Fluo-DLT internalization were dependent on the integrity of primary afferent inputs, the effect of chronic morphine pretreatment on the in vivo internalization of Fluo-DLT was then assessed in rhizotomized animals. Before studying the effect of morphine treatment in deafferented spinal cords, we first needed to determine whether rhizotomy itself would produce changes in the amount of internalized Fluo-DLT. Efficiency of the rhizotomy was ascertained histologically using IB4 immunostaining of nonpeptidergic unmyelinated primary afferents. As can be seen in Figure 8, IB4 immunoreactivity was completely abolished on the side ipsilateral (A') when compared with the side contralateral (A) to the transected roots, indicating complete degeneration of primary afferents at the time of experimentation (10 d postlesion).
View larger version (48K):
[in this window]
[in a new window]
|
Figure 8. A-C, IB4 immunostaining (A, A') and Fluo-DLT labeling (B, B',C,C') in sections from the rat lumbar (L4-5) spinal cord 10 d after unilateral dorsal rhizotomy. Selective disappearance of IB4 immunostaining in the superficial layers of the dorsal horn on the side ipsilateral (A') compared with the side contralateral (A) to the transected roots indicates complete degeneration of nonpeptidergic primary afferent fibers. In nonmorphine-pretreated rats (B, B'), increased internalization of Fluo-DLT is evident in neurons in lamina V on the side ipsilateral (B') compared with contralateral (B) to the transected roots. In morphine-pretreated animals (C,C'), there is no apparent increase in the intensity of Fluo-DLT neuronal labeling on either the ipsilateral (compare C' and B') and contralateral (compare C and B) sides. Images B, B', C, and C' are displayed in red-white glow-scale. Scale bars: A, A', 200 µm; B, B', C, C', 10 µm.
|
|
In rhizotomized rats, intrathecal administration of Fluo-DLT resulted in, as in control nonrhizotomized rats, the labeling of nerve cell bodies throughout the gray matter of the lumbar spinal cord bilaterally (Fig. 8B,B'). However, in contrast to control rats, individual cell bodies in laminas III-IV could no longer be reliably distinguished from background because of an increase in fluorescent puncta over the neuropil (data not shown). Hence, the average number of Fluo-DLT-labeled perikaryal profiles per section was counted only in laminas V-IX. As can be seen in Figure 9A, a statistically greater number of labeled perikaryal profiles was detected in lamina V, but not in laminas VI-IX, on the ipsilateral side of the spinal cord in rhizotomized rats when compared with either the contralateral side (p < 0.001) or the spinal cord of control rats (p < 0.05). In addition, a statistically significant increase in overall fluorescence labeling levels was observed in laminas V-VI of the ipsilateral spinal cord in rhizotomized rats when compared with the contralateral side in the same animals (p < 0.05) (Fig. 9B). Fluorescence labeling levels also appeared to be increased on the side ipsilateral to the rhizotomy when compared with nondeafferentated rats; however, statistical comparisons could not be performed because images for these two different sets of experiments were not acquired using identical parameters. In any event, it should be noted that fluorescence labeling levels in the spinal cord after root transection were more variable than those observed between spinal cords of intact animals. Nonetheless, these data suggest that the dorsal rhizotomy itself, independent from any pharmacological treatment, affects the amount of internalized Fluo-DLT and, hence, OR cell surface density in the ipsilateral dorsal horn.
View larger version (20K):
[in this window]
[in a new window]
|
Figure 9. Effect of unilateral dorsal rhizotomy on Fluo-DLT labeling in the rat lumbar spinal cord. A, An increase in the number of Fluo-DLT-positive profiles is observed in laminas V-VI of the ipsilateral side of nonmorphine-pretreated rhizotomized rats when compared with either the side contralateral to the lesion (two-way ANOVA; Bonferroni's MCT; p < 0.001; denoted by #) or to control nonlesioned (two-way ANOVA; Bonferroni's MCT; p < 0.05; denoted by *) rats. B, Fluorescence labeling levels were significantly greater in nonmorphine-pretreated rhizotomized rats in laminas V-VI of the ipsilateral side compared with the contralateral side of lesioned animals (paired t test; p < 0.05; denoted by *), in agreement with the increase in the number of Fluo-DLT-labeled cells.
|
|
In rhizotomized rats, morphine pretreatment produced no additional increase (over that produced by rhizotomy itself) in the number of Fluo-DLT-labeled perikaryal profiles on the deafferented side of the lumbar spinal cord when compared with the deafferented side of nonmorphine-pretreated rats (Figs. 8B',C', 10A). Likewise, overall fluorescence-labeling levels were not significantly different between morphine-pretreated and non-treated rhizotomized rats in all layers of the spinal cord on the side ipsilateral to the lesion (Fig. 10C). Furthermore, morphine pretreatment no longer produced an increase in the average number of Fluo-DLT-labeled cell body profiles (Figs. 8B,C,10B) or Fluo-DLT-labeling levels (Fig. 10D) in the dorsal horn on the side contralateral to the deafferentation. Thus, a unilateral dorsal rhizotomy abolished µOR-induced changes in the amount of internalized Fluo-DLT bilaterally in the dorsal horn of the rat spinal cord.
View larger version (36K):
[in this window]
[in a new window]
|
Figure 10. Effect of morphine pretreatment on Fluo-DLT labeling in the spinal cord of rats with a unilateral dorsal rhizotomy. A, B, Comparison of the number of Fluo-DLT-labeled perikaryal profiles in laminas V-IX on the contralateral (B) and ipsilateral side (A) reveals no significant difference between non-morphine sulfate (MS)-pretreated and MS-pretreated rats using two-way ANOVA. C, D, No statistically significant difference in Fluo-DLT-labeling levels between non-MS-pretreated and MS-pretreated animals was detected for either the side contralateral (D) or ipsilateral (C) to the transected roots in any of the lamina in the lumbar (L4-5) spinal cord using two-way ANOVA.
|
|
|
Discussion
|
|---|
Methodological considerations
We previously showed that pretreatment with morphine results in enhanced recruitment of OR to neuronal plasma membranes and a concomitant increase in OR-mediated antinociception in the spinal cord of rodents (Cahill et al., 2001b; Morinville et al., 2003). In the current study, we sought to determine the location in the spinal cord of neurons that undergo changes in OR responsiveness in response to morphine pretreatment. To this aim, we developed an assay that indirectly assesses cell surface OR availability through measurement of the amount of a fluorescent OR agonist (Fluo-DLT) internalized via these receptors over a fixed time period. This assay is based on our previous finding that in neurons in culture, the amount of internalized Fluo-DLT is directly related to the density of cell surface OR available for internalization, as determined by immunogold electron microscopy (Cahill et al., 2001b). Although this assay does not afford the same degree of precision as immunogold electron microscopy, it lends itself to more extensive tissue sampling over a wider range of animals/treatments.
In the present study, Fluo-DLT was administered in vivo via the intrathecal route. After allowing for the ligand to diffuse in the spinal cord, rats were perfused with paraformaldehyde to wash out cell surface and nonspecifically bound Fluo-DLT molecules and to trap internalized molecules into endosomes. Accordingly, Fluo-DLT-labeling pattern was highly punctate, as expected for ligand concentrated in early endosomes (Gaudriault et al., 1997).
Fluo-DLT internalization under basal conditions
Intrathecal injection of Fluo-DLT resulted in the labeling of numerous cells in both the dorsal and ventral horn of the rat lumbar (L4-5) spinal cord. These Fluo-DLT-internalizing cells all stained for Neurotracer, in conformity with our previous finding that >95% of OR-immunoreactive elements detected in the superficial layers of the rat lumbar spinal cord were neuronal (Cahill et al., 2001a). Fluo-DLT labeling was inhibited by naloxone, an opioid antagonist, in all laminas of the spinal cord, indicating that it was specific and receptor mediated. The labeling of cells throughout the depth of the spinal cord was surprising. Indeed, it is generally assumed that peptides penetrate tissue poorly, and hence one might have expected that only cells at the edge of the gray matter (i.e., the closest to the spinal cord surface and CSF) would have internalized Fluo-DLT. These findings suggest that spinal diffusion of exogenously applied peptides might be greater than heretofore reported.
The distribution and number of Fluo-DLT-labeled perikaryal profiles matched those of OR-expressing cells detected by immunohistochemistry or in situ hybridization at the same segmental level (Cahill et al., 2001a; our study), suggesting that many neurons expressing ORs had responded to agonist application. In addition to fluorescently labeled neuronal cell bodies, fluorescent puncta were detected throughout the neuropil of the dorsal horn, especially in laminas I-II. These fluorescent puncta could correspond to ligand internalized in axon terminals and cross-sectioned dendrites. Fluo-DLT labeling of axons would be consistent with the reported association of OR with primary afferent axons (Fields et al., 1980; Zajac et al., 1989; Besse et al., 1990, 1992a,b,c; Dado et al., 1993; Elde et al., 1995; Stevens et al., 1995; Abbadie et al., 2002; Mennicken et al., 2003) and the demonstration that peptide ligands may be internalized presynaptically (Nguyen et al., 2002). Fluo-DLT labeling of dendrites would concur with the presence, within laminas I and II, of dendritic arborizations of neurons from deeper layers (Willis and Coggeshall, 1991) and the demonstration of Fluo-DLT internalization in dendrites of neurons in culture (Lee et al., 2002).
Morphine-induced changes in OR availability
A major finding of the present study was the robust increase in the amount of internalized Fluo-DLT in the dorsal horn of the spinal cord after morphine pretreatment for 48 hr. This increase could have resulted from either enhanced OR internalization rate or augmented OR cell surface availability. Because our previous studies demonstrated an increase in OR cell surface density in the dorsal horn of rodents pretreated with morphine (Cahill et al., 2001b; Morinville et al., 2003) and because this increase in cell surface density was shown to translate into enhanced Fluo-DLT internalization in vitro (Cahill et al., 2001b), we interpreted the present results to reflect a selective augmentation in OR cell surface availability rather than an enhancement of OR internalization rate. Both [125I]-DLT-II binding and OR mRNA levels in spinal cord sections from morphine-pretreated rats were similar to those observed in sections from control animals, suggesting that the increase in the amount of internalized Fluo-DLT and, hence, in the availability of cell surface OR was the consequence of a trafficking event and not of an increase in overall OR receptor levels.
GPCR activation by agonists and coupling to intracellular signaling cascades can be monitored by measuring the binding levels of [35S]-GTPS (for review, see Sim et al., 1997). However, DLT-induced GTPS binding was not significantly different between morphine-pretreated and control animals. This lack of effect suggests that the autoradiographic detection of DLT-induced [35S]-GTPS binding levels is less sensitive than the present in vivo internalization technique for detecting changes in pharmacologically available cell surface OR.
We originally hypothesized that changes in OR internalization would be observed throughout the spinal cord because localization studies had demonstrated the presence of µOR in all laminas of the rat spinal cord (Goodman et al., 1980; Gouardères et al., 1991, 1993; Stevens et al., 1991; Hiller et al., 1994; Maekawa et al., 1994; Mansour et al., 1994a,b; Abbadie et al., 2000, 2001). However, the increase in the amount of internalized Fluo-DLT was restricted to the dorsal horn, suggesting that factors more complex than µOR/OR colocalization are involved in regulating OR plasma membrane density. In this context, it is important to recall that the dorsal horn is intimately involved in the processing of primary afferent information, including nociception (for review, see Willis and Coggeshall, 1991), and that µORs located on primary afferent terminals in the dorsal horn presynaptically regulate afferent information (Fields et al., 1980; Zajac et al., 1989; Besse et al., 1990, 1992a,b,c; Gouardères et al., 1991; Mansour et al., 1994a,b; Ding et al., 1995, 1996; Stevens and Seybold, 1995; Abbadie et al., 2002). We therefore hypothesized that µOR agonists acting at the level of incoming afferent fibers might be regulating OR responsiveness throughout the dorsal horn.
Abolition of primary afferent input
After unilateral rhizotomy, we observed a significant increase in the amount of internalized Fluo-DLT in lamina V on the deafferented side when compared with the contralateral side, suggesting that OR availability was enhanced on the lesioned side. In contrast, previous studies have demonstrated dramatic decreases in OR opioid binding (Fields et al., 1980; Zajac et al., 1989; Besse et al., 1990, 1992a,b,c; Stevens and Seybold, 1995) and immunoreactivity (Dado et al., 1993; Abbadie et al., 2002) in ipsilateral laminas I-II after dorsal rhizotomy, presumably reflecting a loss of presynaptic OR. However, none of these studies reported any increase in deeper laminas (Besse et al., 1990, 1991, 1992a,b,c; Stevens and Seybold, 1995; Abbadie et al., 2002), in keeping with our interpretation that binding and immunohistochemical studies, in contrast to the present in vivo internalization assay, label all receptors and not merely pharmacologically responsive ones. Our results therefore suggest that primary afferent inputs regulate the cell surface density of OR in intrinsic dorsal horn neurons through mechanisms that may or may not be dependent on the activation of µOR. They also suggest that pain resulting from damage or degeneration of primary afferent fibers might be particularly sensitive to treatment with OR agonists.
Morphine pretreatment of rats with unilateral dorsal rhizotomy did not lead to any additional increase in the amount of Fluo-DLT internalized on the deafferented side. However, the baseline number of Fluo-DLT-labeled perikaryal profiles on the side of the lesion was comparable with the number Fluo-DLT-labeled profiles in morphine-pretreated, nonrhizotomized rats, suggesting that the maximal number of neurons that could be labeled in lamina V had been attained as a result of rhizotomy itself. Hence, it is unclear whether the lack of morphine effect on the side of the deafferentation was attributable to suppression of presynaptic µORs or to a pre-existing saturation of OR upregulatory mechanisms.
However, chronic morphine treatment also failed to increase Fluo-DLT internalization on the side contralateral to the deafferentation. In this case, the lack of morphine effect could not be attributed to saturation of OR upregulatory mechanisms, because baseline, premorphine treatment levels of Fluo-DLT-labeled cells were the same as in control rats. Therefore, it appears that unilateral dorsal rhizotomy produces changes on the contralateral side such that the cell surface density of ORs can no longer be regulated through chronic stimulation with µOR agonists. Bilateral decreases in µOR-binding sites have been reported in the dorsal horn after unilateral rhizotomy (Besse et al., 1992a,b; Stevens and Seybold, 1995), suggesting that the lack of increase in the amount of Fluo-DLT internalized might result from a decrease in µOR available for the expression of morphine effects. However, other more complex mechanisms could also be involved given the extensive contralateral neuroanatomical changes detected after unilateral injuries (for review, see Koltzenburg et al., 1999). In any event, the present results indicate that the µOR-induced regulation of OR responsiveness in the dorsal horn of the spinal cord is dependent on the integrity of primary afferent inputs and may hence be linked to somatosensory processing.
|
Footnotes
|
|---|
Received May 29, 2003;
revised April 22, 2004;
accepted April 26, 2004.
This work was supported by grants from the Canadian Institutes of Health Research and AstraZeneca awarded to A.B. A.M. was funded by fellowships from the Faculty of Medicine and McGill University. C.M.C. was funded by Merck and Company. We extend our gratitude to Naomi Takeda, Mariette Lavall&
Top
Abstract
Introduction
